Yes, to be fair AFM also retraced quite a bit despite a strong dividend distribution program. Unfortunately, despite the glaring valuation discrepancy vs FCF generation, no fresh capital finds its way to the small and mid-cap mining sector.
- Forums
- ASX - By Stock
- MLX
- 4Q2024 Valuation
4Q2024 Valuation, page-22
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MLX (ASX) to my watchlist
(20min delay)
|
|||||
Last
45.0¢ |
Change
0.010(2.27%) |
Mkt cap ! $403.4M |
Open | High | Low | Value | Volume |
44.5¢ | 45.0¢ | 44.0¢ | $436.6K | 987.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 145 | 44.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
45.0¢ | 168718 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 145 | 0.445 |
3 | 149868 | 0.440 |
2 | 51750 | 0.435 |
3 | 162000 | 0.430 |
4 | 138517 | 0.425 |
Price($) | Vol. | No. |
---|---|---|
0.450 | 168718 | 6 |
0.455 | 19868 | 1 |
0.460 | 152718 | 7 |
0.465 | 106629 | 3 |
0.470 | 287219 | 4 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
LU7
The Breakdown: Lithium Universe talks refinery design and lithium processing in strong preliminary feasibility study for Bécancour
RCE
Phase II clinical trial recruitment for R327G topical gel passes halfway, showing promising results against bacterial skin infections
MLX (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online